PAVM: Reverse Split And Tighter Share Structure Will Reduce Dilution Risk

Analysts have raised their price target on PAVmed significantly, from approximately 5.55 dollars to 9.50 dollars, citing expectations for faster revenue growth, meaningfully improved profit margins, and a lower perceived risk profile.

What's in the News

• Stockholders approved an amendment to PAVmed's certificate of incorporation authorizing a reverse stock split in a range of 1-for-10 to 1-for-30, at the board's discretion (Special Meeting, Dec. 5, 2025).
• The same amendment includes a reduction in authorized common shares from 250,000,000 to 25,000,000, significantly tightening the company's share structure (Special Meeting, Dec. 5, 2025).
• Approximately 65.8 percent of the voting power outstanding and entitled to vote participated in person or by proxy at the special stockholders meeting, signaling strong shareholder engagement (Special Meeting, Dec. 5, 2025).
• The Dec. 5, 2025 special meeting agenda centered on approval of the reverse stock split and the related cut in authorized shares, with authority to adjourn if insufficient votes were received (Special Meeting notice, Dec. 2025).

Valuation Changes

• The fair value estimate has risen significantly, from approximately $5.55 to $9.50 per share.
• The discount rate has fallen modestly, from 11.41 percent to about 9.77 percent, reflecting a lower perceived risk profile.
• The revenue growth projection has increased meaningfully, from roughly 269.43 percent to about 397.91 percent.
• The net profit margin forecast has improved substantially, from about 1.49 percent to approximately 12.91 percent.
• The future P/E multiple has expanded sharply, moving from about 110.77x to roughly 897.22x earnings.